These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

42 related articles for article (PubMed ID: 9015796)

  • 1. Tardive dyskinesia exacerbated after ingestion of phenylalanine by schizophrenic patients.
    Mosnik DM; Spring B; Rogers K; Baruah S
    Neuropsychopharmacology; 1997 Feb; 16(2):136-46. PubMed ID: 9015796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients.
    Silver H; Geraisy N; Schwartz M
    J Clin Psychiatry; 1995 Apr; 56(4):167-70. PubMed ID: 7713856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The acute effects of a loading dose of phenylalanine in unipolar depressed patients with and without tardive dyskinesia.
    Gardos G; Cole JO; Matthews JD; Nierenberg AA; Dugan SJ
    Neuropsychopharmacology; 1992 Jun; 6(4):241-7. PubMed ID: 1352977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The association between risk factors for tardive dyskinesia and phenylalanine-induced abnormal movements in schizophrenia.
    Schultz SK; Ellingrod V; Fleming FW; Andreasen NC
    Hum Psychopharmacol; 2001 Apr; 16(3):273-277. PubMed ID: 12404580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study.
    Bai YM; Yu SC; Lin CC
    J Clin Psychiatry; 2003 Nov; 64(11):1342-8. PubMed ID: 14658949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tardive dyskinesia and impaired glucose tolerance.
    Chong SA; Mythily ; Lum A; Huak CY; Kane J
    Hum Psychopharmacol; 2002 Aug; 17(6):305-7. PubMed ID: 12404676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Lack of involuntary abnormal movements in untreated schizophrenic patients].
    Hernán Silva I; Jerez CS; Ruiz TA; Seguel LM; Court LJ; Labarca BR
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1994; 22(5):200-2. PubMed ID: 7817846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Withdrawal-emergent dyskinesia in patients with schizophrenia during antipsychotic discontinuation.
    Schultz SK; Miller DD; Arndt S; Ziebell S; Gupta S; Andreasen NC
    Biol Psychiatry; 1995 Dec; 38(11):713-9. PubMed ID: 8580223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia.
    Lohr JB; Caligiuri MP
    J Clin Psychiatry; 1996 Apr; 57(4):167-73. PubMed ID: 8601552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic relationship of antisaccade and dyskinesia in schizophrenic patients.
    Cassady SL; Thaker GK; Tamminga CA
    Psychopharmacol Bull; 1993; 29(2):235-40. PubMed ID: 8290671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of the Ser9Gly polymorphism in the dopamine D3 receptor gene with tardive dyskinesia in Korean schizophrenics.
    Woo SI; Kim JW; Rha E; Han SH; Hahn KH; Park CS; Sohn JW
    Psychiatry Clin Neurosci; 2002 Aug; 56(4):469-74. PubMed ID: 12109967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tardive dyskinesia, impaired recall, and informed consent.
    Ganguli R; Raghu U
    J Clin Psychiatry; 1985 Oct; 46(10):434-5. PubMed ID: 2864333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molindone and haloperidol in tardive dyskinesia.
    Glazer WM; Hafez HM; Benarroche CL
    J Clin Psychiatry; 1985 Aug; 46(8 Pt 2):4-7. PubMed ID: 2862139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early course of new-onset tardive dyskinesia in older patients.
    Lacro JP; Gilbert PL; Paulsen JS; Fell R; Bailey A; Juels C; Caligiuri M; McAdams LA; Harris MJ; Jeste DV
    Psychopharmacol Bull; 1994; 30(2):187-91. PubMed ID: 7831454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical effectiveness of the Kampo medicine kamishoyosan for adjunctive treatment of tardive dyskinesia in patients with schizophrenia: a 16-week open trial.
    Lee JG; Shin BS; Lee YC; Park SW; Kim YH
    Psychiatry Clin Neurosci; 2007 Oct; 61(5):509-14. PubMed ID: 17875029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "Positive" and "negative" movement disorders in schizophrenia.
    Sandyk R; Kay SR
    Int J Neurosci; 1992 Oct; 66(3-4):143-51. PubMed ID: 1305614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bereitschaftspotential in tardive dyskinesia.
    Adler LE; Pecevich M; Nagamoto H
    Mov Disord; 1989; 4(2):105-12. PubMed ID: 2733704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyridoxal plasma level in schizophrenic and schizoaffective patients with and without tardive dyskinesia.
    Miodownik C; Meoded A; Libov I; Bersudsky Y; Sela BA; Lerner V
    Clin Neuropharmacol; 2008; 31(4):197-203. PubMed ID: 18670243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The current prevalence and factors associated with tardive dyskinesia among Filipino schizophrenic patients.
    Go CL; Rosales RL; Caraos RJ; Fernandez HH
    Parkinsonism Relat Disord; 2009 Nov; 15(9):655-9. PubMed ID: 19346155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tardive dyskinesia in schizophrenic outpatients: prevalence and significant variables.
    Ezrin-Waters C; Seeman MV; Seeman P
    J Clin Psychiatry; 1981 Jan; 42(1):16-22. PubMed ID: 6109715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.